Advanced Research Center, Inc.

Running trials

• Recruiting

  A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

  NCT07424404· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

  NCT07288567· Phase 3· Source

• Recruiting

  A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

  NCT06951698· Phase 3· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

  NCT06690398· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

  NCT06651567· Phase 2· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

  NCT06540833· Phase 2· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

  NCT06372964· Phase 3· Source

• Enrolling by invitation

  Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

  NCT06245031· Source

• Recruiting

  Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  NCT06229210· Phase 3· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Source

• Active, not recruiting

  Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

  NCT05397639· Phase 3· Source

• Recruiting

  Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

  NCT04743141· Phase 3· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease5 recruiting
• Schizophrenia5 recruiting
• Bipolar disorder4 recruiting
• Autism3 recruiting
• Migraine2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

  NCT06836063· Phase 2· Source

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Source

• Terminated

  BHV-7000 Open-Label Extension Bipolar Mania Study

  NCT06423794· Phase 2· Source

• Completed

  BHV-7000 Acute Treatment of Bipolar Mania

  NCT06419582· Phase 2/3· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· Source

• Completed

  A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

  NCT05628103· Phase 3· Source

• Completed

  A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

  NCT05637801· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Source

• Terminated

  A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

  NCT05227209· Phase 3· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Source

• Terminated

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

  NCT04951609· Phase 1· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Completed

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

  NCT04533529· Phase 3· Source